Fibrobiologics Inc
FBLG0.619USD
-0.030-4.59%
Market hours （ET）Quotes delayed by 15 min
25.29MMarket Cap
LossP/E TTM
More Details of Fibrobiologics Inc Company
FibroBiologics, Inc. is a cell therapy regenerative medicine company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The Company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat Multiple sclerosis (MS) and has completed the Phase I study. The Company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing.
Company Info
Ticker SymbolFBLG
Company nameFibrobiologics Inc
IPO dateJan 31, 2024
CEOMr. Pete O'Heeron
Number of employees13
Security typeOrdinary Share
Fiscal year-endJan 31
Address455 E. Medical Center Blvd
CityHOUSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code77598
Phone12816715150
Websitehttps://fibrobiologics.com/
Ticker SymbolFBLG
IPO dateJan 31, 2024
CEOMr. Pete O'Heeron
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Mr. Richard Cilento, Jr.
Mr. Richard Cilento, Jr.
Independent Director
Independent Director
--
--
Ms. Stacy Coen
Ms. Stacy Coen
Independent Director
Independent Director
--
--
Mr. Matthew Link
Mr. Matthew Link
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Hamid Khoja, Ph.D.
Dr. Hamid Khoja, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
31.25K
+177.78%
Dr. Victoria Niklas, M.D.
Dr. Victoria Niklas, M.D.
Independent Director
Independent Director
7.50K
--
Mr. Robert E. Hoffman, CPA
Mr. Robert E. Hoffman, CPA
Director
Director
7.50K
--
Mr. Nic Johnson
Mr. Nic Johnson
IR Contact Officer
IR Contact Officer
--
--
Mr. Ruben Garcia
Mr. Ruben Garcia
General Counsel
General Counsel
--
--
Mr. Pete O'Heeron
Mr. Pete O'Heeron
Chairman of the Board, Chief Executive Officer, Founder
Chairman of the Board, Chief Executive Officer, Founder
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Jul 28
Updated: Mon, Jul 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
O'Heeron (Peter)
14.10%
Golden Knight Inc LP
5.10%
BlackRock Institutional Trust Company, N.A.
3.90%
The Vanguard Group, Inc.
3.39%
Geode Capital Management, L.L.C.
1.47%
Other
72.05%
Shareholders
Shareholders
Proportion
O'Heeron (Peter)
14.10%
Golden Knight Inc LP
5.10%
BlackRock Institutional Trust Company, N.A.
3.90%
The Vanguard Group, Inc.
3.39%
Geode Capital Management, L.L.C.
1.47%
Other
72.05%
Shareholder Types
Shareholders
Proportion
Individual Investor
15.84%
Investment Advisor
11.61%
Corporation
5.58%
Investment Advisor/Hedge Fund
4.21%
Research Firm
0.60%
Hedge Fund
0.18%
Bank and Trust
0.07%
Venture Capital
0.05%
Pension Fund
0.03%
Other
61.83%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
123
14.61M
38.17%
+89.36K
2025Q1
124
14.64M
40.12%
+123.60K
2024Q4
115
14.16M
40.30%
-9.06K
2024Q3
108
15.43M
44.70%
+1.86M
2024Q2
83
13.39M
40.93%
+2.95M
2024Q1
29
10.41M
31.81%
+483.30K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
O'Heeron (Peter)
5.91M
15.44%
--
--
Apr 21, 2025
Golden Knight Inc LP
2.13M
5.58%
+9.85K
+0.46%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
1.63M
4.27%
-25.68K
-1.55%
Mar 31, 2025
The Vanguard Group, Inc.
1.42M
3.71%
+508.69K
+55.79%
Mar 31, 2025
Geode Capital Management, L.L.C.
614.64K
1.61%
+9.71K
+1.61%
Mar 31, 2025
State Street Global Advisors (US)
566.45K
1.48%
-8.07K
-1.40%
Mar 31, 2025
Cascade Financial Partners, LLC
260.08K
0.68%
-22.52K
-7.97%
Mar 31, 2025
Northern Trust Investments, Inc.
201.64K
0.53%
-13.77K
-6.39%
Mar 31, 2025
UBS Financial Services, Inc.
112.86K
0.29%
-15.33K
-11.96%
Mar 31, 2025
Optivise Advisory Services, LLC
110.10K
0.29%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
